Systematic review of antimicrobial drug prescribing in hospitals. by Davey, P et al.
This paper was originally  publication as: 
 Davey P, Brown E, Fenelon L, Finch R, Gould I, Holmes A, et al.  
Systematic review of antimicrobial drug prescribing in hospitals.  
Emerg Infect Dis [serial on the Internet]. 2006 Feb. Available from 
http://www.cdc.gov/ncidod/EID/vol12no02/05-0145.htm
 
Systematic Review of the Microbiological Outcomes 
of Interventions to Improve Antibiotic Prescribing to 
Hospital Inpatients 
Corresponding author: 
Peter Davey, MD FRCP, Professor of Pharmacoeconomics, Dundee University 
Medical School 
Contact details: 
Health Informatics Centre 
Mackenzie Building 
Kirsty Semple Way  
Dundee DD2 4BF 
Telephone +44 1382 420000 
Fax +44 1382 420010 
Biography: Peter Davey is Honorary Consultant in Infectious Diseases at NHS 
Tayside, one of three consultants running a regional infectious diseases service for a 
population of 350,000. He is Director of the Health Informatics Centre, a 
multidisciplinary group developing innovative methods for linkage and application of 
information from health records. His main research interests are epidemiology of 
antibiotic prescribing or resistance and prescribing quality improvement. 
Authors: Erwin Brown MB BCh, FRCPath, Consultant in Medical Microbiology, 
Frenchay Hospital, Bristol; Lynda Fenelon, FRCPath, Consultant in Medical 
Microbiology, St Vincent’s University Hospital, Dublin; Roger Finch, FRCP, 
FRCPEd, FRCPath, FFPM, Professor of Infectious Diseases, The City Hospital and 
 1
University of Nottingham; Ian Gould, MSc, MBChB, PhD, FRCPE, FRCpath, 
Consultant in Medical Microbiology, Aberdeen Royal Infirmary;  Alison Holmes, 
MA MD FRCP MPH, Senior Lecturer in Hospital Epidemiology & Infection Control, 
Imperial College Hammersmith Hospital, London; Craig Ramsay, BSc, PGDip, PhD, 
Senior Statistician, Health Services Research Unit, University of Aberdeen; Eric 
Taylor, FRCS, Consultant Surgeon, Inverclyde Royal Hospital, Greenock; Phil 
Wiffen, MSc, Director of Training UK Cochrane Centre, Oxford; Mark Wilcox, MD, 
MRCPath, Professor of Medical Microbiology and Clinical Director of Microbiology, 
Infection Prevention and Control, Leeds General Infirmary & University of Leeds. 
Article type: synopsis 
Running head: Microbial Outcome of Hospital Prescribing Interventions 
Keywords: antibiotic policy, antibiotic resistance, Clostridium difficile, hospital 
acquired infection 
Word counts: Abstract 150 words; Text 2353 words. 
Abstract 
Prudent antibiotic prescribing to hospital inpatients has the potential to reduce the 
incidences of antimicrobial resistance and healthcare-associated infection. We 
reviewed the literature from January 1980 to November 2003 to identify rigorous 
evaluations of interventions to improve hospital antibiotic prescribing. We identified 
66 studies with interpretable data of which 16 reported 20 microbiological outcomes: 
Gram negative resistant bacteria (GNRB), 10 studies; Clostridium difficile associated 
diarrhoea (CDAD), 5 studies; vancomycin resistant enterococci (VRE), 3 studies and 
methicillin resistant Staphylococcus aureus (MRSA), 2 studies. Four studies provide 
good evidence that the intervention changed microbial outcomes with low risk of 
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alternative explanations, eight studies provide less convincing evidence and four 
studies were negative. The strongest and most consistent evidence was for CDAD but 
we were able to analyse only the immediate impact of interventions because of non-
standardised durations of follow up. The ability to compare results of studies could be 
substantially improved by standardising methodology and reporting. 
Article summary line: 
Seven of 16 studies reporting microbiological outcome provide good evidence that 
interventions can reduce the incidences of C. difficile associated diarrhoea and 
antimicrobial resistance but the evidence base could be substantially improved by 
standardising methodology and reporting. 
Background 
Despite strenuous efforts to control antibiotic usage and to promote optimal 
prescribing, practitioners continue to prescribe excessively and it is estimated that up 
to 50% of antibiotic usage in hospitals is inappropriate(1-3). Antibiotic resistance is 
largely a consequence of the selective pressures of antibiotic usage and it is plausible 
that reducing these pressures by the judicious administration of antibiotics will 
facilitate a return of susceptible bacteria or, at least, will prevent or slow the pace of 
the emergence of resistant strains(4;5). Furthermore Clostridium difficile associated 
diarrhoea (CDAD) is a hospital acquired infection that is associated with antibiotic 
prescribing (6),(7;8) and reducing the incidences of CDAD is an additional potential 
benefit from improving hospital antibiotic prescribing.   
Implementing and monitoring interventions to optimise antibiotic prescribing 
places a burden on hospital resources and their efficacies need to be confirmed.(9).  
We have conducted a systematic review of interventions to improve antibiotic 
prescribing practices for hospital inpatients using the methods of the Cochrane 
 3
Effective Practice and Organisation of Care Group to assess validity (10). In this 
paper our primary objective is to evaluate the impact of interventions on reducing the 
incidence of colonisation with or infection caused by antimicrobial resistant 
pathogens or CDAD. In addition to the usual threats to the validity of interventions to 
change healthcare, infection control interventions are particularly prone to regression 
to the mean.(11) Simply put this refers to the natural tendency of extreme 
observations to return towards the average (mean) over time. An epidemic or outbreak 
is a sequence of unusually large number of cases of infection, so that the natural 
history of an epidemic is to increase, peak and then decline. Consequently regression 
to the mean is always a threat to the validity of evaluations of unplanned interventions 
that are initiated in response to an outbreak.  
Methods 
The full protocol is available in the Cochrane Library (10). We searched 
Medline, EMBASE, the Cochrane database and the EPOC specialised register from 1st 
January 1980 to 30th November 2003 for studies relating to antibiotic prescribing to 
hospital inpatients and additional studies were obtained from the bibliographies of 
retrieved articles, the Scientific Citation Index and personal files. We requested 
additional data from the authors when necessary. There were no language limitations 
for the literature review. We included all randomised and controlled clinical trials 
(RCT/CCT, designs where allocation to the intervention is determined either by an 
explicit random process [RCT] or by a non-random process such as date of birth or 
case note number), controlled before and after studies (CBA, a design where there is 
contemporaneous data collection before and after the intervention and an appropriate 
control site or activity) and interrupted time series (ITS, a design where there is a 
clearly defined point in time when the intervention occurred and at least three data 
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points before and three after the intervention). Data about microbiological outcomes 
were considered reliable if they met the same criteria. For example, if a paper 
included prescribing data that met the criteria for an ITS but provided only mean data 
about microbiological outcomes before and after the intervention then the 
microbiological data were not considered reliable. Two reviewers independently 
extracted data and assessed the quality of each study using the above standardised 
criteria. 
Statistical considerations 
There are many statistical methods that can be used to analyse ITS designs (eg 
ARIMA modelling or time series regression), however the design is often analysed 
inappropriately making interpretation of individual studies difficult (ref Ramsay 
IJTAHC). Methods of analysing ITS data were examined critically (ref Ramsay 
IJTAHC). The preferred method for short time series is segmented time series 
regression analysis, which is a statistical comparison of time trends before and after 
the intervention to identify either an immediate change in the level of the regression 
line or a sustained change in the slope of the line (12)(ref Ramsay). In this paper we 
have distinguished two intervention effects:  immediate (a sudden change in the level 
of the regression line at the point of intervention) and sustained (a sustained change in 
the slope of the regression line from the start of the intervention phase. If the original 
paper did not include an appropriate analysis, the data were re-analysed using 
segmented time series regression. The following model was specified: 
Yt = B0 + B1*Preslope + B2*Postslope + B3*intervention + et
Where Yt is the outcome (eg CDAD incidence) in month t, Preslope is a 
continuous variable indicating time from the start of the study upto the last point in 
the pre intervention phase and coded constant thereafter. Postslope is coded 0 upto 
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and including the first point post intervention and coded sequentially from 1 
thereafter. Intervention is coded 0 for pre intervention time points and 1 for post 
intervention timepoints.  In this model, B1 estimates the slope of the pre intervention 
data, B2 estimates the slope of the post intervention data and B3 estimates the change 
in level of outcome as the difference between the estimated first point post 
intervention and the extrapolated first point post intervention if the preintervention 
line was continued into the post intervention phase.  The difference in slope is 
calculated by B2-B1.  The error term et was assumed to be first order autoregressive. 
Confidence intervals (95%) were calculated for all effect measures. 
Formal meta-analysis of results was not attempted given the differences in 
context, setting and type of outcomes. However, to gain an overall summary picture 
of the heterogeneity of effect sizes we standardised all measures so that they were all 
on the same scale.  To do this, we divided the change in level and the change in slope 
by the pre-intervention standard deviation (SD) in each study.  The resulting metric 
has no unit and in standard meta-analysis it is known as the standardised mean 
difference. Standardised effect sizes of 2 to 3 standard deviations were considered 
large, whereas an effect size of <0.5 standard deviation was considered of 
questionable clinical significance even if statistically significant (13).  To visually 
display the heterogeneity of the standardised effect sizes, graphical plots of level 
effects versus slope effects for each study (with associated 95% confidence intervals) 
were generated. 
Other Criteria for Assessment of Evidence 
The statistical analysis assessed how likely it was that study results could 
simply have happened by chance and the Cochrane quality criteria assessed common 
threats to the validity of interventions to change practice or the organisation of care . 
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In order to assess other threats to validity of infection control interventions we used 
the format for reporting the results of included studies recommended by guidelines 
derived from a recent systematic review of isolation measures to control MRSA (14). 
Ideally we required studies to provide reliable data about the effect of interventions on 
both microbial and drug outcomes with clear case definition, description of infection 
control measures and other variables such as bed occupancy or staffing levels that 
could provide plausible alternative explanations for changes in microbial outcomes. 
We have provided a summary of the evidence from the included studies (Table 1) 
with more detailed information about each study in an appendix on the EID web site. 
We classified case definitions  into colonization, infection or clinical isolates or a 
combination of two or more with the following definitions: 
Colonization: the presence of a microorganism, usually detected by screening, at a 
host site (normally nonsterile, although the bladder urine of a catheterized patient may 
be an exception) without causing systemic signs of infection or a specific immune 
response.   
Colonization by case note review:  established by excluding infection diagnosed 
according to criteria adopted by the authors or defined by authoritative bodies, e.g., 
the CDC criteria for diagnosing nosocomial infections." 
Infection:  established by case note review according to criteria adopted by the authors 
or defined by authoritative bodies or by recording specific symptoms and/or signs, 
such as diarrhea in patients with CDAD." 
Clinical isolates: recovery of a microorganism following culture of a clinical (not 
screening) specimen without specifying whether it represents colonization or 
infection. 
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Results 
We identified 66 studies of interventions to improve antibiotic prescribing to 
hospital inpatients that met our inclusion criteria (15) and excluded 243 studies that 
were uncontrolled before and after studies (n=164) or inadequate ITS studies (n=79). 
Of the 66 included studies 16 reported reliable data about 20 microbiological 
outcomes: Gram negative resistant bacteria (GNRB), 10 studies; CDAD, 5 studies; 
vancomycin resistant enterococci (VRE), 3 studies and methicillin resistant 
Staphylococcus aureus (MRSA), 2 studies (Table 1). The setting for the intervention 
was the whole hospital in eight studies (16-23), a single service in two studies(24;25) 
and a unit or ward in six studies(26-31). One intervention was educational, with 
advice about changes in antibiotics (16), whereas the other 15 interventions were 
restrictive (Table 1). There were two RCTs (30;31)and one CCT (29); the remaining 
13 studies used an ITS design. 
Statistical validity 
All three clinical trials involved appropriate statistical analysis (29),(30;31) 
whereas only two of the 13 ITS studies reported appropriate statistical 
analysis(16;26). Of the remaining 11 ITS studies five did not report statistical analysis 
and six reported inappropriate analysis using tests such as chi-square or t tests that 
assume independence between observations and take no account of time trends. Data 
from these 11 studies were re-analysed.  
Evidence for effectiveness of interventions to improve antibiotic prescribing 
Overall, four studies provide good evidence of control of the microbial outcome by 
change in prescribing. (16;26;29;30) All of these studies provide reliable data about 
antibiotic prescribing with significant changes in both microbial and drug outcomes 
following planned interventions. In addition two studies provided further protection 
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against regression to the mean by using a cross over design (26;29). Three of these 
studies have rigorous case definition based on prospective screening cultures plus full 
description of infection control measures.  
 Eight studies provide less convincing evidence. Two studies showed 
significant changes in prescribing that were associated with non-signficant changes in 
CDAD(19;25).There are an additional six studies that report statistically significant 
improvement in microbial outcome but without reliable data about the effect of the 
intervention on prescribing  (17;18;22;23;27;28). The importance of this omission is 
confirmed by the six studies that did include reliable data about prescribing because 
all of them showed that there was some prescription of restricted drugs during the 
intervention phase.(16;19;25;26;29;30) 
There are four negative studies (20;21;24;31). One study provide good evidence of 
failure to control microbial outcomes despite a successful change in prescribing (31). 
One study reports an intervention that failed to change vancomycin use(21). The 
remaining two studies show no change in microbial outcome but do not provide 
reliable data about the effect of the intervention on prescribing (20;24).  
CDAD 
The most consistent evidence was for the five interventions designed to reduce 
the incidence of CDAD. Four were implemented in the whole hospital (16;17;19;23) 
and one in the care of the elderly service (25); all five targeted cephalosporin or 
clindamycin prescribing. All of the interventions were associated with a change in the 
expected direction (Figure 1a), which was a change in the incidence of CDAD in the 
same direction to change in cephalosporin or clindamycin use. For one intervention 
the expected direction was an increase in CDAD incidence after the introduction of 
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ceftriaxone (19); for all other interventions a decrease in CDAD incidence was 
expected to accompany decrease in cephalosporin or clindamycin use. These five 
studies reported a total of seven interventions. The immediate effect after six of the 
seven interventions was at least 0.5 SDs and five of these seven immediate effects 
were statistically significant (Figure 1a). Sustained changes after the intervention were 
more modest but all in the expected directions and four of seven were statistically 
significant (Figure 1a.). The five CDAD studies presented their results in different 
units: cases per month (23;25); cases per quarter (17;19) or cases per 1000 admissions 
per year (16). Consequently we were only able to compare effect sizes in numbers of 
CDAD cases per quarter by recalculating results from two studie (23;25). The 
antibiotic intervention was associated with a mean immediate reduction of 15.0 
CDAD cases per quarter (range, 6 to 26) and a median sustained reduction of 3.2 
CDAD cases per quarter (range,1 to 6).   
GNRB 
The results of the 10 interventions designed to reduce the incidences of GNRB 
were less consistent. Three were implemented in the whole hospital (18;20;22), one 
was implemented on the neurology and neurosurgery service (24) and five in a single 
intensive care unit, four of which were paediatric (27-29;31) and one adult(30). One 
intervention was designed to reduce the duration of treatment with any antibiotic for 
ICU patients at low risk of pneumonia and this was associated with a significant 
reduction in the incidence of colonisation by any GNRB and in exposure to antibiotics 
(30). The remaining nine interventions involved changes in antibiotic treatment 
targeted mainly at aminoglycosides or cephalosporins. One RCT provided no 
evidence that antibiotic cycling reduced the incidence of GNRB in a neonatal ICU 
(31). The eight ITS studies reported nine outcomes (Figure 1b). The expected 
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direction of effect from a change in aminoglycoside or cephalosporin prescribing was 
usually a reduction in GNRB. For one intervention the expected direction of effect 
was an increase in the incidence of GNRB after re-introducing gentamicin (18). There 
was a change in level in the expected direction for all nine outcomes but the effect 
size was <0.5 SD in two studies and was not statistically significant in five (Figure 
1b). In only three studies were the changes in slope in the expected direction and in 
only one was both statistically significant and >0.5 SD, which is likely to be clinically 
significant. Unlike the CDAD data it is not possible to express effects in a common 
unit. Some studies measured colonisation and others examined infection. Units of 
measurement were also variable (e.g. number of isolates, percentage of isolates, 
number of cases and number of cases per time period). 
Gram-positive bacteria 
Data for Gram-positive bacteria are very limited. One study provided 
convincing evidence that restriction of ceftazidime on a haematology unit was 
associated with significant reduction in risk of colonisation by VRE (26). However, 
reduction of cephalosporin use in a hospital was not associated with any change in the 
prevalence of VRE isolates (16). A third study targeted at VRE showed that 
implementation of a vancomycin order form had no significant impact on vancomycin 
prescribing, with a trend in the unintended direction (21). Two studies report effects 
on MRSA prevalence(16;20).Our segmented regression analysis showed that there 
was no significant change in response to a reduction in use of third generation 
cephalosporins (Table 1), although one of the papers claimed that there was a change 
(20). 
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Discussion 
Our primary conclusion is that four of the 16 studies provide good evidence 
that changes in antibiotic prescribing to hospital inpatients can improve microbial 
outcomes (16;26)(29)(30). Eight of the remaining studies provide some evidence that 
antibiotic prescribing interventions can improve microbial outcomes but flaws in their 
design meant that there were plausible alternative explanations for the results (17-
19;22;23;25;27;28). The remaining four studies were unequivocally negative 
(20;21;24;31). 
Estimation of overall effect size was only possible for reduction in CDAD, 
where the evidence suggests that restriction of clindamycin or third generation 
cephalosporins resulted in an immediate reduction in prevalence by 15 cases per 
quarter with a further sustained reduction by 3 cases per quarter. It is usual to adjust 
prevalence for clinical activity, for example cases per 1000 admissions per quarter (7) 
but only one study provided this information (16). Furthermore there were potentially 
important differences in the case definitions of CDAD between the studies in our 
review. 
The second conclusion is that finding valid studies required painstaking 
analysis of a huge volume of literature, most of which is fundamentally flawed (15). 
Even the included studies could be dramatically improved by following guidelines for 
standardised reporting (14).  In particular, the unequal duration of post-intervention 
phases made it difficult to reliably compare the sustained effects of interventions, 
these being the most important outcome measures. The short and unequal duration of 
pre-intervention phases provides limited information about underlying pre-
intervention trends. In order to understand how much of a change in prescribing is 
required to change outcome the intervention must be independent of other control 
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measures and be accompanied by reliable data about both prescribing and microbial 
outcomes. 
Only one of the interventions was designed to reduce overall exposure to 
antibiotics (30), all of the others being targeted at the choice of antibiotic. This study 
was conducted in an adult ICU but the same principle of using clinical scores to 
identify low risk patients, in whom antibiotic therapy could be stopped has been 
developed in other clinical settings(32-34) and the impact on microbiological 
outcomes should be investigated. 
Crucially none of the studies provided evidence for cost-effectiveness or 
clinical outcome. Furthermore it is likely that the study designs did not have sufficient 
power to measure these outcomes. Only a minority of studies provided data about 
multiple microbiological species and one of these endpoints (incidence of cefotaxime-
resistant Acinetobacter spp.) was in the opposite direction to that which was expected 
(20). Future studies should provide more data about cost and clinical outcomes. 
Notably, evidence is needed to show that interventions do not have adverse outcomes. 
It seems likely that the potential for the success of antimicrobial interventions 
varies by organism (35;36). Anti-infectives are likely to play a large role in the 
selection of Enterobacteriaciaea expressing ESBLs, a minimal role in the selection 
and tranmission of MRSA, and an intermediate role in VRE. However, at present the 
available evidence is not sufficient to investigate these hypotheses. 
Implications for practice 
The evidence supports the theory that limiting the use of specific antibiotics 
will reduce the prevalences of resistant Gram-negative bacteria and CDAD. For 
Gram-positive bacteria there is a lack of evidence rather than evidence of no effect. 
 13
Ideally hospitals would like to know by how much they should limit their antibiotic 
prescriptions and what is the minimum that they must cut down to see a “real” effect. 
Unfortunately the available evidence is too limited to provide definitive answers to 
these questions, consequently hospitals must estimate the effect of their own 
interventions. The good news is that the data required for ITS analysis of the 
incidences of resistant bacteria or CDAD should be readily available in most 
hospitals. Healthcare providers need to invest in data analysis so that evaluation of 
antibiotic control in single hospitals becomes a routine measure of the quality of care 
rather than a research project. 
Standardised reporting of outbreaks and interventions to control the incidence 
of antibiotic resistance or hospital acquired infection would greatly enhance the ability 
to combine results from hospitals in meta-analyses. Key issues include full description 
of other infection control measures, consistent and reproducible case definitions, the 
length of pre- and post-intervention phases and the time intervals between data points. 
Ideally data should be presented or made available in a way that allows re-analysis 
and where appropriate meta-analysis. Meta-analysis of single hospital studies is no 
substitute for good multi-centre studies but could be used to provide some evidence of 
reproducibility and hence to prioritise targets for definitive trials. 
Priorities for research 
The research agenda needs to move to multi-centre studies with randomised 
allocation to interventions. This will provide better evidence of external validity as 
well as the power to measure cost-effectiveness and exclude important unintended 
adverse clinical outcomes.   
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Development and pilot testing of the effectiveness of clinical decision rules for 
reducing unnecessary exposure to antibiotics should be a priority for research in 
single hospitals. 
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 to
 a
 U
ni
ve
rs
ity
) i
n 
th
e 
U
SA
. N
o 
ob
st
et
ric
 u
ni
t 
or
 p
ae
di
at
ric
 IC
U
. 
 
H
yb
rid
 re
tro
sp
ec
tiv
e 
an
d 
pr
os
pe
ct
iv
e 
In
te
rr
up
te
d 
Ti
m
e 
Se
rie
s w
ith
 tw
o 
ph
as
es
 o
f 3
6 
an
d 
84
 m
on
th
s. 
 
Pl
an
ne
d 
in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: i
nf
ec
tio
n 
w
ith
 
C
D
A
D
 o
r r
es
is
ta
nt
 g
ra
m
-
ne
ga
tiv
e 
ba
ct
er
ia
, M
R
SA
 o
r 
V
R
E.
 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 c
on
si
st
en
t t
hr
ou
gh
 
st
ud
y.
 
Ph
as
e 
1:
 a
ut
om
at
ic
 7
 d
ay
 st
op
 
or
de
r o
n 
al
l a
nt
ib
io
tic
s, 
lim
ite
d 
re
po
rti
ng
 o
f s
us
ce
pt
ib
ili
ty
 te
st
s, 
an
d 
ed
uc
at
io
na
l p
ro
gr
am
m
e.
 
Ph
as
e 
2:
 a
s P
ha
se
 1
 p
lu
s r
ev
ie
w
 
of
 p
at
ie
nt
s r
ec
ei
vi
ng
 ta
rg
et
 
an
tib
io
tic
s b
y 
ph
ar
m
ac
is
t a
nd
 ID
 
ph
ys
ic
ia
n,
 re
co
m
m
en
da
tio
ns
 
pl
ac
ed
 in
 th
e 
ca
se
 n
ot
es
. 
M
ic
ro
bi
al
: C
D
A
D
 a
nd
 re
si
st
an
t 
En
te
ro
ba
ct
er
ia
ce
ae
 in
 c
as
es
 p
er
 1
00
0 
ad
m
is
si
on
s. 
M
R
SA
 a
nd
 V
R
E 
as
 %
 c
lin
ic
al
 
is
ol
at
es
. 
Po
st
 in
te
rv
en
tio
n 
th
er
e 
w
er
e 
si
gn
ifi
ca
nt
 
re
du
ct
io
ns
  f
or
 C
D
A
D
: i
m
m
ed
ia
te
 -1
.4
7 
ca
se
s, 
p<
0.
00
1;
 su
st
ai
ne
d 
 -0
.8
1 
ca
se
s, 
p=
0.
05
. R
es
is
ta
nt
 E
nt
er
ob
ac
te
ria
ce
ae
 a
ls
o 
re
du
ce
d:
 im
m
ed
ia
te
 -2
.3
4 
ca
se
s, 
p=
0.
03
; 
su
st
ai
ne
d 
-1
.3
4 
ca
se
s, 
p=
0.
01
. T
he
re
 w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 th
e 
%
 is
ol
at
es
 o
f 
M
R
SA
 o
r V
R
E.
 
D
ru
g:
 a
ut
ho
rs
’ r
eg
re
ss
io
n 
an
al
ys
is
 sh
ow
s 
si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 ta
rg
et
 a
nt
ib
io
tic
s i
n 
Ph
as
e 
2.
 
Si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 C
D
A
D
 
ca
se
s a
nd
 re
si
st
an
t 
En
te
ro
ba
ce
ria
ce
ae
 a
ss
oc
ia
te
d 
w
ith
 p
la
nn
ed
 a
nt
ib
io
tic
 
in
te
rv
en
tio
n 
th
at
 re
su
lte
d 
in
 
si
gn
ifi
ca
nt
 c
ha
ng
es
 in
 a
nt
ib
io
tic
 
us
e.
  
M
ai
n 
w
ea
kn
es
se
s a
re
 th
e 
la
ck
 o
f 
de
ta
il 
ab
ou
t i
nf
ec
tio
n 
co
nt
ro
l a
nd
 
th
e 
ca
se
 d
ef
in
iti
on
 fo
r r
es
is
ta
nt
 
En
te
ro
ba
ct
er
ia
ce
ae
. 
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St
ud
y 
Se
tt
in
g 
an
d 
po
pu
la
tio
n 
D
es
ig
n 
M
ai
n 
in
te
rv
en
tio
ns
 
O
ut
co
m
es
 
A
ss
es
sm
en
t o
f e
vi
de
nc
e 
C
lim
o 
19
98
 (1
7)
 
Si
ng
le
 7
03
 b
ed
 te
rti
ar
y 
ca
re
 
ho
sp
ita
l i
n 
th
e 
U
SA
. 
H
yb
rid
 re
tro
sp
ec
tiv
e 
an
d 
pr
os
pe
ct
iv
e 
In
te
rr
up
te
d 
Ti
m
e 
Se
rie
s w
ith
 tw
o 
ph
as
es
 o
f 2
7 
an
d 
33
 m
on
th
s. 
 
U
np
la
nn
ed
 in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: i
nf
ec
tio
n,
 
C
D
A
D
. 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 c
on
si
st
en
t t
hr
ou
gh
 
st
ud
y.
 
Ph
as
e 
1:
 in
fe
ct
io
n 
co
nt
ro
l o
nl
y 
Ph
as
e 
2:
 in
fe
ct
io
n 
co
nt
ro
l p
lu
s  
re
st
ric
tio
n 
of
 c
lin
da
m
yc
in
. 
M
ic
ro
bi
al
: C
D
A
D
 c
as
es
 p
er
 q
ua
rte
r. 
Th
e 
in
te
rv
en
tio
n 
w
as
 a
ss
oc
ia
te
d 
w
ith
 
si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 C
D
A
D
 c
as
es
 p
er
 
qu
ar
te
r: 
im
m
ed
ia
te
 -2
6.
3 
ca
se
s, 
p<
0.
00
1;
 
su
st
ai
ne
d 
-3
.8
 c
as
es
, p
<0
.0
01
. 
D
ru
g:
 n
o 
re
lia
bl
e 
da
ta
. 
 
Si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 C
D
A
D
 
ca
se
s i
n 
Ph
as
e 
2.
 
H
ow
ev
er
, t
hi
s w
as
 a
n 
un
pl
an
ne
d 
in
te
rv
en
tio
n,
 th
er
e 
ar
e 
no
 re
lia
bl
e 
da
ta
 a
bo
ut
 d
ru
g 
us
e 
an
d 
th
e 
st
ud
y 
ha
s s
ev
er
al
 o
th
er
 p
ot
en
tia
lly
 
im
po
rta
nt
 w
ea
kn
es
se
s. 
 
de
 C
ha
m
ps
 e
t a
l 
19
94
 (2
8)
 
Si
ng
le
 p
ae
di
at
ric
 IC
U
 w
ith
 
15
 v
en
til
at
or
 b
ed
s a
nd
 2
8 
in
te
rm
ed
ia
te
 c
ar
e 
be
ds
 in
 
Fr
an
ce
. 
Pr
os
pe
ct
iv
e 
In
te
rr
up
te
d 
Ti
m
e 
Se
rie
s w
ith
 tw
o 
ph
as
es
 o
f 7
 a
nd
 
12
 m
on
th
s. 
 
U
np
la
nn
ed
 in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: i
nf
ec
tio
n 
by
 
re
si
st
an
t E
 c
lo
ac
ae
. 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 c
on
si
st
en
t t
hr
ou
gh
 
st
ud
y.
 
Ph
as
e 
1:
 b
ar
rie
r p
re
ca
ut
io
ns
 
on
ly
. 
Ph
as
e 
2:
 b
ar
rie
r p
re
ca
ut
io
ns
 p
lu
s 
re
m
ov
al
 o
f g
en
ta
m
ic
in
 fr
om
 th
e 
un
it 
an
d 
re
pl
ac
em
en
t b
y 
am
ik
ac
in
. 
M
ic
ro
bi
al
: T
he
 in
te
rv
en
tio
n 
w
as
 a
ss
oc
ia
te
d 
w
ith
 si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 re
si
st
an
t E
 
cl
oa
ca
e 
ca
se
s p
er
 m
on
th
, i
m
m
ed
ia
te
 -7
.4
7 
ca
se
s, 
p<
0.
00
1;
 su
st
ai
ne
d 
-1
.0
0 
ca
se
s, 
p=
0.
00
2.
 
D
ru
g:
 n
o 
re
lia
bl
e 
da
ta
. 
Si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 E
 
cl
oa
ca
e 
ca
se
s i
n 
Ph
as
e 
2.
 
H
ow
ev
er
, t
hi
s w
as
 a
n 
un
pl
an
ne
d 
in
te
rv
en
tio
n,
 th
er
e 
ar
e 
no
 re
lia
bl
e 
da
ta
 a
bo
ut
 d
ru
g 
us
e 
an
d 
th
e 
st
ud
y 
ha
s s
ev
er
al
 o
th
er
 p
ot
en
tia
lly
 
im
po
rta
nt
 w
ea
kn
es
se
s. 
 
de
 M
an
 e
t a
l 2
00
1 
(2
9)
 
Tw
o 
si
m
ila
r n
eo
na
ta
l I
C
U
s 
in
 th
e 
sa
m
e 
ho
sp
ita
l. 
Th
e 
st
ud
y 
en
ro
lle
d 
43
6 
pa
tie
nt
s 
w
ith
 a
 m
ea
n 
of
 3
3 
w
ee
ks
 
ge
st
at
io
n.
 
Pr
os
pe
ct
iv
e 
cl
us
te
r c
on
tro
lle
d 
cl
in
ic
al
 tr
ia
l w
ith
 c
ro
ss
ov
er
 w
ith
 
tw
o 
ph
as
es
 o
f s
ix
 m
on
th
s e
ac
h.
  
Pl
an
ne
d 
in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: c
ol
on
iz
at
io
n 
pl
us
 c
lin
ic
al
 is
ol
at
es
. 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 c
on
si
st
en
t t
hr
ou
gh
 
st
ud
y.
 
Ph
as
e 
1:
 U
ni
t A
 u
se
d 
am
ox
ic
ill
in
 
pl
us
 c
ef
ot
ax
im
e,
 U
ni
t B
 u
se
d 
pe
ni
ci
lli
n 
pl
us
 to
br
am
yc
in
. 
Ph
as
e 
2:
 T
he
 a
nt
ib
io
tic
 p
ol
ic
ie
s 
w
er
e 
sw
ap
pe
d 
ov
er
: U
ni
t A
 u
se
d 
pe
ni
ci
lli
n 
pl
us
 to
br
am
yc
in
, U
ni
t 
B
 u
se
d 
am
ox
ic
ill
in
 p
lu
s 
ce
fo
ta
xi
m
e.
 
M
ic
ro
bi
al
:T
he
 c
ef
ot
ax
im
e 
&
 a
m
ox
ic
ill
in
 
re
gi
m
en
 w
as
 a
ss
oc
ia
te
d 
w
ith
 a
 re
la
tiv
e 
ris
k 
of
 c
ol
on
is
at
io
n 
by
 G
ra
m
-n
eg
at
iv
e 
ba
ct
er
ia
 
re
si
st
an
t t
o 
ce
fo
ta
xi
m
e 
or
 to
br
am
yc
in
 o
f 
2.
98
 (C
I 1
.6
4 
to
 5
.3
8)
. 
D
ru
g:
 C
ef
ot
ax
im
e 
pl
us
 a
m
ox
ic
ill
in
 
ex
po
su
re
 w
as
 2
6%
-3
2%
 o
f p
at
ie
nt
 d
ay
s 
w
he
n 
th
at
 re
gi
m
en
 w
as
 in
 p
la
ce
 v
s. 
1%
 w
he
n 
pe
ni
ci
lli
n 
pl
us
 to
br
am
yc
in
 w
as
 in
 p
la
ce
.  
Si
gn
ifi
ca
nt
ly
 in
cr
ea
se
d 
ris
k 
of
 
co
lo
ni
sa
tio
n 
as
so
ci
at
ed
 w
ith
 th
e 
ce
fo
ta
xi
m
e 
&
 a
m
ox
ic
ill
in
 
re
gi
m
en
.  
H
ow
ev
er
, r
is
k 
of
 c
ol
on
is
at
io
n 
w
as
 a
ls
o 
re
la
te
d 
to
 le
ng
th
 o
f s
ta
y 
an
d 
th
is
 w
as
 si
gn
ifi
ca
nt
ly
 sh
or
te
r 
in
 th
e 
pe
ni
ci
lli
n 
pl
us
 to
br
am
yc
in
 
ph
as
e.
 
G
er
di
ng
 e
t a
l 
19
85
 (1
8)
 
Si
ng
le
 V
et
er
an
s 
A
dm
in
is
tra
tio
n 
ho
sp
ita
l i
n 
th
e 
U
SA
. 
Pr
os
pe
ct
iv
e 
In
te
rr
up
te
d 
Ti
m
e 
Se
rie
s w
ith
 fo
ur
 p
ha
se
s o
f 4
, 2
6,
 
12
 a
nd
 1
2 
m
on
th
s. 
 
Pl
an
ne
d 
in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: c
lin
ic
al
 is
ol
at
es
. 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:n
ot
 d
es
cr
ib
ed
. 
Ph
as
e 
1:
 n
o 
re
st
ric
tio
n.
 
Ph
as
e 
2:
 g
en
ta
m
ic
in
 re
st
ric
te
d.
 
Ph
as
e 
3:
 a
m
ik
ac
in
 re
st
ric
te
d.
 
Ph
as
e 
4:
 g
en
ta
m
ic
in
 re
st
ric
te
d.
 
M
ic
ro
bi
al
: %
 o
f a
ll 
gr
am
-n
eg
at
iv
e 
ae
ro
bi
c 
ba
ci
lli
  r
es
is
ta
nt
 to
 g
en
ta
m
ic
in
. 
Fi
gu
re
 1
 o
f t
he
 p
ap
er
 sh
ow
s r
es
is
ta
nc
e 
to
 
ge
nt
am
ic
in
 v
ar
ie
d 
be
tw
ee
n 
15
%
 a
nd
 2
%
 
ov
er
 th
e 
st
ud
y,
 fa
lli
ng
 a
nd
 ri
si
ng
 w
ith
 n
o 
cl
ea
r r
el
at
io
ns
hi
p 
to
 c
ha
ng
es
 in
 a
nt
ib
io
tic
 
po
lic
y.
 
D
ru
g:
 n
o 
re
lia
bl
e 
da
ta
. 
Li
ttl
e 
ev
id
en
ce
 th
at
 th
e 
flu
ct
ua
tio
ns
 in
 re
si
st
an
ce
 to
 
ge
nt
am
ic
in
 w
er
e 
re
la
te
d 
to
 
an
tib
io
tic
 p
ol
ic
y 
ch
an
ge
s. 
Se
ve
ra
l p
ot
en
tia
lly
 im
po
rta
nt
 
de
si
gn
 w
ea
kn
es
se
s. 
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St
ud
y 
Se
tt
in
g 
an
d 
po
pu
la
tio
n 
D
es
ig
n 
M
ai
n 
in
te
rv
en
tio
ns
 
O
ut
co
m
es
 
A
ss
es
sm
en
t o
f e
vi
de
nc
e 
K
ha
n 
20
03
 (1
9)
 
Si
ng
le
 8
00
 b
ed
 n
on
-te
ac
hi
ng
 
ho
sp
ita
l i
n 
th
e 
U
K
. 
Pr
os
pe
ct
iv
e 
In
te
rr
up
te
d 
Ti
m
e 
Se
rie
s w
ith
 th
re
e 
ph
as
es
 o
f 6
, 1
3 
an
d 
5 
m
on
th
s. 
 
Ph
as
e 
2 
pl
an
ne
d,
 P
ha
se
 3
 
un
pl
an
ne
d.
 
C
as
e 
de
fin
iti
on
: C
D
A
D
 
in
fe
ct
io
n.
 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 c
on
si
st
en
t t
hr
ou
gh
 
st
ud
y.
 
Ph
as
e 
1:
 c
ef
ot
ax
im
e.
 
Ph
as
e 
2:
 c
ef
tri
ax
on
e.
 
Ph
as
e 
3:
 le
vo
flo
xa
ci
n.
 
 
M
ic
ro
bi
al
: P
ha
se
 2
 w
as
 a
ss
oc
ia
te
d 
w
ith
 
in
cr
ea
se
 in
 C
D
A
D
 c
as
es
 p
er
 q
ua
rte
r: 
im
m
ed
ia
te
 +
19
.7
 c
as
es
, p
=0
.0
7;
 su
st
ai
ne
d 
+4
.7
 c
as
es
 p
=0
.0
7.
 P
ha
se
 3
 w
as
 a
ss
oc
ia
te
d 
w
ith
 su
st
ai
ne
d 
re
du
ct
io
n 
in
 C
D
A
D
 b
y 
-5
.8
 
ca
se
s p
er
 q
ua
rte
r, 
p=
0.
08
.  
D
ru
g:
 n
o 
re
lia
bl
e 
da
ta
 fo
r P
ha
se
 1
, 
si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 c
ef
tri
ax
on
e 
us
e 
(G
 
pe
r q
ua
rte
r)
 in
 P
ha
se
 3
. 
N
on
 si
gn
ifi
ca
nt
 c
ha
ng
es
 in
  
C
D
A
D
 w
er
e 
as
so
ci
at
ed
 w
ith
 th
e 
in
tro
du
ct
io
n 
an
d 
re
st
ric
tio
n 
of
 
ce
ftr
ia
xo
ne
.  
R
eg
re
ss
io
n 
to
 th
e 
m
ea
n 
is
 a
 
pl
au
si
bl
e 
al
te
rn
at
iv
e 
ex
pl
an
at
io
n 
fo
r c
ha
ng
es
 in
 P
ha
se
 3
 a
nd
 
re
lia
bl
e 
dr
ug
 d
at
a 
ar
e 
on
ly
 
pr
ov
id
ed
 fo
r P
ha
se
s 2
 a
nd
 3
.. 
La
nd
m
an
 1
99
0 
(2
0)
 
Si
ng
le
 U
ni
ve
rs
ity
 h
os
pi
ta
l i
n 
th
e 
U
SA
 w
ith
 5
69
 
di
sc
ha
rg
es
 p
er
 m
on
th
 fr
om
 
m
ed
ic
al
 a
nd
 su
rg
ic
al
 
se
rv
ic
es
. 
R
et
ro
sp
ec
tiv
e 
In
te
rr
up
te
d 
Ti
m
e 
Se
rie
s w
ith
 tw
o 
ph
as
es
 o
f 2
9 
an
d 
23
 m
on
th
s. 
Pl
an
ne
d 
in
te
rv
en
tio
n.
  
C
as
e 
de
fin
iti
on
: c
lin
ic
al
 is
ol
at
es
 
of
 re
si
st
an
t b
ac
te
ria
. 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s: 
no
ne
 sp
ec
ifi
c 
to
 th
e 
ba
ct
er
ia
 u
nd
er
 st
ud
y.
 
Ph
as
e 
1:
 u
nr
es
tri
ct
ed
. 
Ph
as
e 
2:
 re
st
ric
tio
n 
of
 th
ird
-
ge
ne
ra
tio
n 
ce
ph
al
os
po
rin
s, 
cl
in
da
m
yc
in
 a
nd
 v
an
co
m
yc
in
 b
y 
re
qu
iri
ng
 a
pp
ro
va
l b
y 
an
 ID
 
ph
ys
ic
ia
n.
  
M
ic
ro
bi
al
: T
he
 in
te
rv
en
tio
n 
w
as
 n
ot
 
as
so
ci
at
ed
 w
ith
 a
 si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 th
e 
in
ci
de
nc
e 
of
 e
ith
er
 c
ef
ta
zi
di
m
e-
re
si
st
an
t 
K
le
bs
ie
lla
 p
ne
um
on
ia
e 
or
 M
R
SA
. H
ow
ev
er
, 
th
er
e 
w
as
 a
 si
gn
ifi
ca
nt
 su
st
ai
ne
d 
in
cr
ea
se
 in
 
ce
fo
ta
xi
m
e-
re
si
st
an
t A
ci
ne
to
ba
ct
er
 sp
p:
 b
y 
+0
.3
37
 n
ew
 c
as
es
 p
er
 1
,0
00
 d
is
ch
ar
ge
s. 
D
ru
g:
 n
o 
re
lia
bl
e 
da
ta
. 
Th
e 
in
te
rv
en
tio
n 
w
as
 a
ss
oc
ia
te
d 
w
ith
 a
 si
gn
ifi
ca
nt
 b
ut
 u
ni
nt
en
de
d 
in
cr
ea
se
 in
 o
ne
 o
f t
he
 o
ut
co
m
es
 
an
d 
no
 si
gn
ifi
ca
nt
 c
ha
ng
es
 in
 th
e 
ot
he
r. 
H
ow
ev
er
 th
er
e 
ar
e 
im
po
rta
nt
 w
ea
kn
es
se
s i
n 
th
e 
st
ud
y 
de
si
gn
.  
La
ut
en
ba
ch
 2
00
3 
(2
1)
 
Si
ng
le
 7
25
 b
ed
 U
ni
ve
rs
ity
 
ho
sp
ita
l i
n 
th
e 
U
SA
. 
H
yb
rid
 re
tro
sp
ec
tiv
e 
an
d 
pr
os
pe
ct
iv
e 
IT
 w
ith
 tw
o 
ph
as
es
 
of
 3
6 
an
d 
84
 m
on
th
s. 
 
U
np
la
nn
ed
 in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: c
lin
ic
al
 is
ol
at
es
 
of
 V
R
E.
 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 n
ot
 d
es
cr
ib
ed
. 
Ph
as
e 
1:
 u
nr
es
tri
ct
ed
 u
se
 o
f 
an
tib
io
tic
s. 
Ph
as
e 
2:
 u
se
 o
f v
an
co
m
yc
in
 o
r 
th
ird
 g
en
er
at
io
n 
ce
ph
al
os
po
rin
s 
fo
r >
72
h 
re
qu
ire
d 
ap
pr
ov
al
 b
y 
th
e 
A
nt
im
ic
ro
bi
al
 M
an
ag
em
en
t 
Te
am
. A
fte
r 2
4 
m
on
th
s a
ny
 u
se
 
of
 v
an
co
m
yc
in
 re
qu
ire
d 
ap
pr
ov
al
.  
M
ic
ro
bi
al
: R
eg
re
ss
io
n 
an
al
ys
is
 su
gg
es
ts
 
th
at
 th
e 
in
te
rv
en
tio
n 
w
as
 a
ss
oc
ia
te
d 
w
ith
 
si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 %
V
R
E 
bu
t t
hi
s 
re
su
lt 
w
as
 a
n 
ar
te
fa
ct
 c
au
se
d 
by
 th
e 
fir
st
 
po
in
t i
n 
th
e 
da
ta
 (1
%
 V
R
E)
 a
nd
 o
nl
y 
ha
vi
ng
 
th
re
e 
pr
e-
in
te
rv
en
tio
n 
po
in
ts
. 
D
ru
g:
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 v
an
co
m
yc
in
 
us
e 
(D
D
D
/1
00
0 
pa
tie
nt
 d
ay
s)
 
N
o 
ev
id
en
ce
 su
pp
or
tin
g 
co
nt
ro
l 
by
 a
nt
ib
io
tic
 re
st
ric
tio
n 
be
ca
us
e 
th
e 
re
st
ric
tio
n 
cl
ea
rly
 d
id
 n
ot
 
re
du
ce
 th
e 
us
e 
of
 v
an
co
m
yc
in
.  
N
o 
da
ta
 a
bo
ut
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s a
nd
 th
er
e 
ar
e 
ot
he
r 
im
po
rta
nt
 w
ea
kn
es
se
s i
n 
th
e 
st
ud
y 
de
si
gn
. 
 
Le
ve
rs
te
in
 v
an
 
H
al
l e
t a
l 2
00
1 
(2
4)
 
N
eu
ro
lo
gy
 a
nd
 n
eu
ro
su
rg
er
y 
w
ar
ds
 in
 a
 si
ng
le
 8
58
 b
ed
 
U
ni
ve
rs
ity
 h
os
pi
ta
l i
n 
th
e 
N
et
he
rla
nd
s. 
Pr
os
pe
ct
iv
e 
IT
S 
w
ith
 tw
o 
ph
as
es
 
of
 1
 a
nd
 2
 m
on
th
s. 
 
U
np
la
nn
ed
 in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: c
ol
on
iz
at
io
n.
 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 c
on
si
st
en
t t
hr
ou
gh
 
st
ud
y 
bu
t o
nl
y 
im
pl
em
en
te
d 
fo
ur
 
w
ee
ks
 b
ef
or
e 
th
e 
st
ar
t o
f 
an
tib
io
tic
 re
st
ric
tio
n.
 
Ph
as
e 
1:
 st
rin
ge
nt
 b
ar
rie
r 
pr
ec
au
tio
ns
. 
Ph
as
e 
2:
 re
st
ric
tio
n 
of
 a
ll 
an
tib
io
tic
s b
y 
re
qu
iri
ng
 a
pp
ro
va
l 
by
 m
ic
ro
bi
ol
og
y 
or
 ID
. O
nl
y 
am
ik
ac
in
 o
r c
ar
ba
pe
ne
m
s 
al
lo
w
ed
 fo
r t
re
at
m
en
t o
f G
ra
m
-
ne
ga
tiv
e 
in
fe
ct
io
n.
 
M
ic
ro
bi
al
: %
 p
re
va
le
nc
e 
of
 in
te
st
in
al
 
co
lo
ni
za
tio
n 
by
 g
en
ta
m
ic
in
 re
si
st
an
t 
En
te
ro
ba
ct
er
ai
ac
ea
e 
w
as
 d
ec
lin
in
g 
pr
e 
in
te
rv
en
tio
n:
 b
y 
-1
.3
 %
 p
er
 w
ee
k 
an
d 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
po
st
-in
te
rv
en
tio
n.
 
D
ru
g:
 n
o 
re
lia
bl
e 
da
ta
. 
N
o 
ev
id
en
ce
 su
pp
or
tin
g 
co
nt
ro
l 
by
 a
nt
ib
io
tic
 re
st
ric
tio
n.
  
Th
er
e 
ar
e 
se
ve
ra
l i
m
po
rta
nt
 
w
ea
kn
es
se
s i
n 
th
e 
st
ud
y 
de
si
gn
.. 
M
cN
ul
ty
 e
t a
l 
19
97
 (2
5)
 
C
ar
e 
of
 th
e 
el
de
rly
 u
ni
t i
n 
a 
si
ng
le
 n
on
-te
ac
hi
ng
 h
os
pi
ta
l 
in
 th
e 
U
K
. 
Pr
os
pe
ct
iv
e 
IT
S 
w
ith
 tw
o 
ph
as
es
 
of
 7
 a
nd
 1
6 
m
on
th
s. 
  
U
np
la
nn
ed
 in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: i
nf
ec
tio
n,
 
C
D
A
D
. 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 c
on
si
st
en
t t
hr
ou
gh
 
st
ud
y.
 
Ph
as
e 
1:
 in
cr
ea
se
d 
w
ar
d 
cl
ea
ni
ng
 
an
d 
pa
tie
nt
 is
ol
at
io
n.
 
Ph
as
e 
2:
 re
st
ric
tio
n 
of
 
ce
ph
al
os
po
rin
s b
y 
re
m
ov
al
 fr
om
 
w
ar
d 
st
oc
k;
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s a
s i
n 
Ph
as
e 
1.
 
M
ic
ro
bi
al
: P
ha
se
 2
 w
as
 a
ss
oc
ia
te
d 
w
ith
 
no
n-
si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 C
D
A
D
: 
im
m
ed
ia
te
 -3
.2
2,
 c
as
es
 p
er
 m
on
th
 p
=0
.1
20
; 
su
st
ai
ne
d 
–0
.5
0 
ca
se
s p
er
 m
on
th
 p
=0
.2
30
. 
D
ru
g:
 In
te
rv
en
tio
n 
w
as
 a
ss
oc
ia
te
d 
w
ith
 
si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 c
ef
ur
ox
im
e 
co
st
: 
im
m
ed
ia
te
 -£
50
1.
78
 p
er
 m
on
th
, p
=0
.0
15
. 
N
on
-s
ig
ni
fic
an
t r
ed
uc
tio
n 
in
 
C
D
A
D
 c
as
es
. 
Th
is
 w
as
 a
n 
un
pl
an
ne
d 
in
te
rv
en
tio
n 
an
d 
th
e 
st
ud
y 
ha
s 
se
ve
ra
l o
th
er
 p
ot
en
tia
lly
 
im
po
rta
nt
 w
ea
kn
es
se
s. 
 
 
19
 
St
ud
y 
Se
tt
in
g 
an
d 
po
pu
la
tio
n 
D
es
ig
n 
M
ai
n 
in
te
rv
en
tio
ns
 
O
ut
co
m
es
 
A
ss
es
sm
en
t o
f e
vi
de
nc
e 
M
ey
er
 e
t a
l 1
99
3 
(2
2)
 
A
 si
ng
le
 4
87
 b
ed
 U
ni
ve
rs
ity
 
ho
sp
ita
l i
n 
th
e 
U
SA
. 
H
yb
rid
 re
tro
sp
ec
tiv
e 
an
d 
pr
os
pe
ct
iv
e 
IT
S 
w
ith
 tw
o 
ph
as
es
 
of
 1
4 
an
d 
11
 m
on
th
s. 
U
np
la
nn
ed
 in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: i
nf
ec
tio
n 
pl
us
 
co
lo
ni
za
tio
n.
 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 b
ar
rie
r p
re
ca
ut
io
ns
 
im
pl
em
en
te
d 
at
 th
e 
sa
m
e 
tim
e 
as
 
ce
fta
zi
di
m
e 
re
st
ric
tio
n.
 
Ph
as
e 
1:
 u
su
al
 c
ar
e.
 
Ph
as
e 
2:
 b
ar
rie
r p
re
ca
ut
io
ns
 fo
r 
in
fe
ct
ed
 o
r c
ol
on
iz
ed
 p
at
ie
nt
s 
pl
us
 re
st
ric
tio
n 
of
 c
ef
ta
zi
di
m
e.
 
 C
as
e 
no
te
s w
er
e 
re
vi
ew
ed
 fo
r 
13
3 
of
 th
e 
14
2 
pa
tie
nt
s w
ith
 
re
si
st
an
t i
so
la
te
s, 
of
 w
ho
m
 5
2 
(3
9%
) m
et
 C
D
C
 c
rit
er
ia
 fo
r 
no
so
co
m
ia
l i
nf
ec
tio
n.
 
M
ic
ro
bi
al
: N
um
be
r o
f c
as
es
 o
f c
ef
ta
zi
di
m
e 
re
si
st
an
t K
 p
ne
um
on
ia
e 
pe
r 1
00
0 
av
er
ag
e 
da
ily
 c
en
su
s. 
Ph
as
e 
2 
w
as
 a
ss
oc
ia
te
d 
w
ith
 
si
gn
ifi
ca
nt
 re
du
ct
io
n:
 im
m
ed
ia
te
 -3
8.
6 
ca
se
s, 
p<
0.
00
01
; s
us
ta
in
ed
 -6
.2
 c
as
es
, p
<0
.0
00
1.
  
D
ru
g:
 D
ru
g 
da
ta
 a
re
 p
ro
vi
de
d 
fo
r d
iff
er
en
t 
pe
rio
ds
 (2
2 
m
on
th
s p
re
 a
nd
 6
 m
on
th
s p
os
t) 
bu
t d
o 
sh
ow
 a
 si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 th
e 
nu
m
be
r o
f p
at
ie
nt
s r
ec
ei
vi
ng
 c
ef
ta
zi
di
m
e:
 
im
m
ed
ia
te
 -2
6.
4 
pa
tie
nt
s, 
p=
.0
03
; s
us
ta
in
ed
  
-1
0.
21
 p
at
ie
nt
s, 
p<
0.
00
1.
  
Si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 
ce
fta
zi
di
m
e 
re
si
st
an
t K
 
pn
eu
m
on
ia
e 
in
 P
ha
se
 2
 w
ith
 
si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 
ce
fta
zi
di
m
e 
us
e.
  
H
ow
ev
er
, i
t i
s i
m
po
ss
ib
le
 to
 
se
pa
ra
te
 th
e 
ef
fe
ct
 o
f c
ef
ta
zi
di
m
e 
re
st
ric
tio
n 
fr
om
 th
e 
in
fe
ct
io
n 
co
nt
ro
l m
ea
su
re
s. 
R
eg
re
ss
io
n 
to
 
th
e 
m
ea
n 
is
 a
no
th
er
 p
la
us
ib
le
 
ex
pl
an
at
io
n.
  
Pe
ar
 e
t a
l 1
99
4 
(2
3)
 
A
 si
ng
le
 U
ni
ve
rs
ity
 h
os
pi
ta
l 
in
 th
e 
U
SA
 w
ith
 a
n 
av
er
ag
e 
da
ily
 c
en
su
s o
f 1
68
 p
at
ie
nt
s. 
H
yb
rid
 re
tro
sp
ec
tiv
e 
an
d 
pr
os
pe
ct
iv
e 
IT
S 
w
ith
 tw
o 
ph
as
es
 
of
 4
0 
an
d 
14
 m
on
th
s. 
U
np
la
nn
ed
 in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: i
nf
ec
tio
n,
 
C
D
A
D
. 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 c
on
si
st
en
t a
cr
os
s 
st
ud
y.
 
Ph
as
e 
1:
 h
os
pi
ta
l s
ta
ff
 e
du
ca
tio
n,
 
in
cr
ea
se
d 
us
e 
of
 g
lo
ve
s a
nd
 
im
pr
ov
ed
 e
nv
iro
nm
en
ta
l 
hy
gi
en
e.
 
Ph
as
e 
2:
 re
st
ric
tio
n 
of
 
cl
in
da
m
yc
in
 b
y 
pr
io
r a
pp
ro
va
l b
y 
ID
 p
hy
si
ci
an
; i
nf
ec
tio
n 
co
nt
ro
l 
m
ea
su
re
s m
ai
nt
ai
ne
d 
as
 in
 P
ha
se
 
1.
 
M
ic
ro
bi
al
: N
um
be
r o
f C
D
A
D
 c
as
es
 p
er
 
m
on
th
. P
ha
se
 2
 w
as
 a
ss
oc
ia
te
d 
w
ith
 
si
gn
ifi
ca
nt
 re
du
ct
io
n,
 im
m
ed
ia
te
 -3
.6
8 
ca
se
s 
pe
r m
on
th
, p
=0
.0
41
, s
us
ta
in
ed
 -0
.3
2 
ca
se
s 
pe
r m
on
th
, p
=0
.1
34
). 
D
ru
g:
 n
o 
re
lia
bl
e 
da
ta
. 
Si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 C
D
A
D
 
in
 P
ha
se
 2
 b
ut
 th
is
 w
as
 a
n 
un
pl
an
ne
d 
in
te
rv
en
tio
n 
an
d 
th
er
e 
ar
e 
no
 re
lia
bl
e 
da
ta
 a
bo
ut
 d
ru
g 
us
e.
 
Si
ng
h 
et
 a
l 2
00
0 
(3
0)
 
A
du
lt 
su
rg
ic
al
 a
nd
 m
ed
ic
al
 
IC
U
s i
n 
a 
si
ng
le
 U
ni
ve
rs
ity
 
af
fil
ia
te
d 
V
et
er
an
s 
A
dm
in
st
ra
tio
n 
ho
sp
ita
l i
n 
th
e 
U
SA
. 8
1 
pa
tie
nt
s 
in
cl
ud
ed
, m
ea
n 
ag
e 
69
 y
ea
rs
. 
R
an
do
m
is
ed
 tr
ia
l w
ith
 fo
llo
w
 u
p 
of
 p
at
ie
nt
s u
nt
il 
th
ey
 w
er
e 
di
sc
ha
rg
ed
 fr
om
 IC
U
 o
r d
ie
d.
  
Pl
an
ne
d 
in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: c
ol
on
iz
at
io
n 
pl
us
 c
lin
ic
al
 is
ol
at
es
. 
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 n
ot
 d
es
cr
ib
ed
 b
ut
 it
 is
 
re
as
on
ab
le
 to
 a
ss
um
e 
th
at
 th
ey
 
w
er
e 
co
ns
is
te
nt
 fo
r t
he
 
in
te
rv
en
tio
n 
an
d 
co
nt
ro
l p
at
ie
nt
s. 
C
on
tro
l g
ro
up
: C
ho
ic
e,
 n
um
be
r 
an
d 
du
ra
tio
n 
of
 a
nt
ib
io
tic
s a
t t
he
 
di
sc
re
tio
n 
of
 th
e 
ca
re
 p
ro
vi
de
rs
. 
In
te
rv
en
tio
n 
gr
ou
p:
 p
at
ie
nt
s 
re
ce
iv
ed
 st
an
da
rd
is
ed
 in
iti
al
 
th
er
ap
y 
(c
ip
ro
flo
xa
ci
n 
IV
 fo
r 3
 
da
ys
) w
ith
 a
ss
es
sm
en
t a
t 3
 d
ay
s 
w
he
n 
an
tib
io
tic
s w
er
e 
st
op
pe
d 
if 
th
e 
pa
tie
nt
 w
as
 ju
dg
ed
 to
 b
e 
at
 
lo
w
 ri
sk
 o
f p
ne
um
on
ia
 b
as
ed
 o
n 
th
e 
C
PI
S 
sc
or
e.
. 
M
ic
ro
bi
al
:  
%
 p
at
ie
nt
s c
ol
on
iz
ed
 o
r i
nf
ec
te
d 
w
ith
 re
si
st
an
t b
ac
te
ria
. R
el
at
iv
e 
ris
k 
fo
r 
in
te
rv
en
tio
n 
vs
. c
on
tro
l: 
0.
36
, C
I 0
.1
4-
0.
89
 
D
ru
g:
 R
el
at
iv
e 
ris
k 
of
 re
ce
iv
in
g 
an
tib
io
tic
s 
fo
r >
 3
da
ys
, i
nt
er
ve
nt
io
n 
vs
. c
on
tro
l: 
0.
29
, 
C
I 0
.1
7-
0.
48
.  
C
lin
ic
al
: ;
 le
ng
th
 o
f I
C
U
 st
ay
 (9
.4
 d
ay
s 
In
te
rv
en
tio
n 
 v
s 1
4.
7 
da
ys
 C
on
tro
l; 
P 
=0
.0
4)
; 
N
on
 si
gn
ifi
ca
nt
 re
du
ct
io
n 
in
 m
or
ta
lit
y:
 
re
la
tiv
e 
ris
k 
of
 3
0 
da
y 
m
or
ta
lit
y:
 0
.4
1,
 C
I 
0.
16
-1
.0
5 
St
at
is
tic
al
ly
  s
ig
ni
fic
an
t 
re
du
ct
io
n 
in
 ri
sk
 o
f c
ol
on
is
at
io
n 
an
d 
in
fe
ct
io
n 
w
ith
 re
si
st
an
t 
ba
ct
er
ia
 a
ss
oc
ia
te
d 
w
ith
 
re
du
ct
io
n 
in
 a
nt
ib
io
tic
 
pr
es
cr
ib
in
g.
  
C
lin
ic
al
 n
on
-in
fe
rio
rit
y 
of
 th
e 
In
te
rv
en
tio
n 
re
gi
m
en
 w
as
 
co
nf
irm
ed
. 
N
o 
m
aj
or
 w
ea
kn
es
se
s. 
To
ltz
is
 e
t a
l 2
00
2 
(3
1)
 
Si
ng
le
 3
8-
be
d 
ne
on
at
al
 
in
te
ns
iv
e 
ca
re
 u
ni
t i
n 
a 
U
ni
ve
rs
ity
 h
os
pi
ta
l i
n 
th
e 
U
SA
; 1
06
2 
ep
is
od
es
 o
f c
ar
e 
in
 in
fa
nt
s w
ith
 m
ea
n 
ag
e 
35
 
w
ee
ks
. 
R
an
do
m
is
ed
 tr
ia
l w
ith
 fo
llo
w
 u
p 
of
 p
at
ie
nt
s u
nt
il 
th
ey
 w
er
e 
di
sc
ha
rg
ed
 fr
om
 IC
U
 o
r d
ie
d.
  
Pl
an
ne
d 
in
te
rv
en
tio
n.
 
C
as
e 
de
fin
iti
on
: c
ol
on
iz
at
io
n.
  
O
th
er
 in
fe
ct
io
n 
co
nt
ro
l 
m
ea
su
re
s:
 n
ot
 d
es
cr
ib
ed
 b
ut
 it
 is
 
re
as
on
ab
le
 to
 a
ss
um
e 
th
at
 th
ey
 
w
er
e 
co
ns
is
te
nt
 fo
r t
he
 
in
te
rv
en
tio
n 
an
d 
co
nt
ro
l p
at
ie
nt
s. 
C
on
tro
l g
ro
up
:  
pr
es
cr
ib
in
g 
ac
co
rd
in
g 
to
 in
di
vi
du
al
 
pr
ef
er
en
ce
 o
f p
hy
si
ci
an
s. 
In
te
rv
en
tio
n 
gr
ou
p:
 m
on
th
ly
 
ro
ta
tio
n 
be
tw
ee
n 
ge
nt
am
ic
in
, 
fo
llo
w
ed
 b
y 
pi
pe
ra
ci
lli
n-
ta
zo
ba
ct
am
 fo
llo
w
ed
 b
y 
ce
fta
zi
di
m
e 
fo
llo
w
ed
 b
y 
ge
nt
am
ic
in
 a
ga
in
 e
tc
.  
M
ic
ro
bi
al
: %
 o
f p
at
ie
nt
s c
ol
on
iz
ed
 w
ith
 
re
si
st
an
t b
ac
te
ria
. R
el
at
iv
e 
ris
k 
w
as
 g
re
at
er
 
in
 th
e 
In
te
rv
en
tio
n 
gr
ou
p:
 1
.4
0,
 C
I 0
.9
5-
2.
05
. 
D
ru
g:
 T
he
 C
on
tro
l p
at
ie
nt
s r
ec
ei
ve
d 
pr
ed
om
in
an
tly
 g
en
ta
m
ic
in
. T
he
 In
te
rv
en
tio
n 
gr
ou
p 
re
ce
iv
ed
 th
e 
in
te
nd
ed
 a
nt
ib
io
tic
s o
n 
84
%
 o
f a
ll 
an
tib
io
tic
 d
ay
s. 
N
o 
di
ff
er
en
ce
 in
 
to
ta
l a
nt
ib
io
tic
 u
se
. 
C
lin
ic
al
: A
ll 
ca
us
e 
m
or
ta
lit
y 
w
as
 si
m
ila
r: 
3.
2%
 In
te
rv
en
tio
n 
vs
 2
.3
%
 C
on
tro
l. 
N
o 
ev
id
en
ce
 su
pp
or
tin
g 
co
nt
ro
l 
of
 re
si
st
an
ce
 b
y 
an
tib
io
tic
 
cy
cl
in
g.
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Figure 1a: Standardised immediate and sustained effects for Clostridium difficile Associated Diarrhoea 
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Figure 1b: Standardised immediate and sustained effects for resistant Gram-negative bacteria. 
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